Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma's Patience Pays Off: Patient Advocates Are Powerful Allies in Part D

This article was originally published in RPM Report

Executive Summary

The pharmaceutical industry has long counted on patient advocates as allies in the FDA drug approval process. But their relationship on issues related to drug coverage has often been tense. The Medicare drug benefit has opened a new chapter in the relationship. Patient advocates have worked closely with the Centers for Medicare & Medicaid Services in the early months of Part D, and they have had an impact. Industry's long-time effort to establish alliances is paying off.

You may also be interested in...

The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities

Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.

The Xenazine Formula: Is it a Viable Model for Others?

Despite its ultra-orphan indication, Xenazine is likely to provide a very attractive return on its development costs. It's a model that could work for other drugs-but only when several key factors work together.

With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?

The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts